Key Features of Retatrutide LY-3437943
⚠️ For laboratory research use only. Not intended for human or animal consumption.
⚠️ RESEARCH USE ONLY – This product is intended for laboratory research purposes only. Not for human consumption, veterinary use, or as a dietary supplement. By purchasing, you confirm you are a qualified researcher conducting lawful research in compliance with all applicable regulations.
Retatrutide is a cutting-edge research peptide developed by Eli Lilly that represents a breakthrough in metabolic regulation. Unlike single or dual-agonist peptides, Retatrutide simultaneously activates three critical metabolic receptors—GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and Glucagon—delivering comprehensive effects on weight loss, glucose homeostasis, lipid metabolism, and cardiovascular health.
Currently under Phase 2 clinical investigation, Retatrutide has demonstrated superior weight loss efficacy compared to existing GLP-1 monotherapies and dual-agonist therapies, making it a high-priority compound for obesity and metabolic disease research.
Retatrutide’s groundbreaking efficacy stems from its ability to simultaneously engage three distinct receptor pathways involved in metabolic regulation:
GLP-1 is an incretin hormone released by the gut in response to food intake. By activating GLP-1 receptors, Retatrutide:
Research Impact: GLP-1 activation is the cornerstone of Semaglutide’s (Wegovy/Ozempic) weight loss effects, providing 15% weight reduction in clinical trials.
GIP is another gut-derived incretin hormone that complements GLP-1 signaling. Retatrutide’s GIP receptor activation:
Research Impact: Dual GLP-1/GIP agonism (Tirzepatide/Mounjaro) achieves 20% weight loss by combining appetite suppression with enhanced metabolic efficiency.
Glucagon is traditionally known for raising blood glucose, but controlled glucagon receptor activation in the context of GLP-1/GIP co-agonism produces unique metabolic benefits:
Research Impact: The addition of glucagon receptor activation is what differentiates Retatrutide from Tirzepatide, enabling 24.2% weight loss—4% more than dual-agonist therapies.
🔬 Triple-Agonist Synergy: By activating all three receptors, Retatrutide balances insulin secretion (GLP-1/GIP), appetite suppression (GLP-1), metabolic efficiency (GIP), and fat burning (Glucagon)—creating a comprehensive metabolic remodeling effect not achievable with single or dual agonists.
| Dosage | Weight Loss (48 weeks) | Subjects |
|---|---|---|
| Placebo | -1.1% | Obese, non-diabetic |
| Retatrutide 8mg (weekly) | -22.8% | Obese, non-diabetic |
| Retatrutide 12mg (weekly) | -24.2% | Obese, non-diabetic (PRIMARY ENDPOINT) |
Source: Jastreboff AM, et al. (2023). New England Journal of Medicine (NEJM) – Phase 2 clinical trial data.
| Compound | Mechanism | Weight Loss |
|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist only | ~15% |
| Tirzepatide (Mounjaro) | GLP-1/GIP dual agonist | ~20% |
| Retatrutide (LY-3437943) | GLP-1/GIP/Glucagon triple agonist | 24.2% |
📈 Research Insight: Retatrutide achieves 4-9% greater weight loss than current best-in-class therapies, making it the most potent anti-obesity compound in clinical development as of 2024.
| Half-Life | Approximately 6 days (~144 hours) |
| Administration Route | Subcutaneous injection (weekly dosing) |
| Typical Research Dosage | 5-12mg weekly (escalate gradually) |
| Peak Plasma Concentration | 24-72 hours post-injection |
| Molecular Weight | 4867.34 g/mol |
| Molecular Formula | C₂₀₉H₃₃₀N₅₆O₆₅S₂ |
⏱️ Dosing Convenience: The 6-day half-life allows for once-weekly administration, improving research protocol compliance compared to daily injection peptides.
| Chemical Name | Retatrutide (LY-3437943) |
| CAS Number | 2381090-94-2 |
| Molecular Formula | C₂₀₉H₃₃₀N₅₆O₆₅S₂ |
| Molecular Weight | 4867.34 g/mol |
| Appearance | White to off-white lyophilized powder |
| Purity | ≥99% (HPLC verified by Janoshik Analytical) |
| Solubility | Soluble in sterile water, bacteriostatic water, or saline |
| Storage Conditions | Lyophilized: -20°C (stable 24+ months) Reconstituted: 2-8°C (stable 28 days) |
| pH Range (Reconstituted) | pH 4.0-8.0 (stable) |
| Available Sizes | 5mg, 15mg, 30mg, 100mg vials |
📄 Documentation Included:
TIRZEPATIDE
RETATRUTIDE
SEMAGLUTIDE
CAGRILINTIDE
AOD9604
BPC-157
TB-500
GHK-CU
ELORALINTIDE
KLOW
KPV
CJC-1295
IPAMORELIN
TESAMORELIN
EPITHALON
NAD+
SELANK
PT-141
⚠️ RESEARCH USE ONLY
All products listed on this website are intended for laboratory and research purposes only. These products are NOT for human or animal consumption, NOT dietary supplements, and NOT intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm you are a qualified researcher and will use these materials in compliance with all applicable laws. These statements have not been evaluated by the FDA.
LCDP Fitness is your convenient and private online source for highest purity, quality certification, safety delivery peptides.
Ordering from us, your information with the highest remain encrypted standards protected and 100% discreet.
